Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

New Methods Based on Detecting Circulating Tumor Cells Aim to Diagnose and Treat Cancer at Much Earlier Stages

New Methods Based on Detecting Circulating Tumor Cells Aim to Diagnose and Treat Cancer at Much Earlier Stages

In our previous article, we learned about the role of circulating tumor cells in cancer. Because these cells provide information on the disease course, the patient's treatment response, cancer origin and the genetic abnormality causing it, they can be considered “real-time fluid biopsies,” also called liquid biopsies. Capturing them is very difficult, however. Because they are present in very small amounts, specially designed analytical techniques and devices are required. Recent research detected, in 1 mL of blood, 1-10 circulating tumor cells.

Methods based on cells' biological and physical characteristics are used to capture them in blood. Biological characteristics include proteins produced by the cell and receptors carried on its surface. Physical characteristics involve factors such as size, density and the electrical charge carried by the cell.

To Isolate Cancer Cells, Cells in the Blood Sample Are Separated by Density

Circulating tumor cells generally occur in the density layer containing white blood cells. Because these tumor cells are larger than white blood cells, they are subsequently filtered out of the blood. New-generation methods were needed because this method's success in capturing tumor cells is very low.

So far, only one method in this field has received approval from the United States Food and Drug Administration (FDA). Called Cell Search, this system is based on recognizing proteins on the cell surface. Unlike normal blood cells, circulating tumor cells carry a molecule called Epithelial Cell Adhesion Molecule (EpCAM) on their surfaces. Researchers captured these cells by developing an antibody that recognizes and binds to this protein. In the FDA-approved version, magnetic particles were added to the antibodies, allowing the cells bound to them to be readily separated from the sample using a magnetic field.

In a system called Maintrac, rare tumor cells in blood are identified under a microscope. This time, a molecule emitting a signal under certain conditions is attached to proteins recognizing and binding the previously mentioned EpCAM molecule. Samples examined with microscopes designed for this purpose can therefore readily reveal circulating tumor cells.

The main problem in EpCAM-based analyses is that many circulating tumor cells no longer carry this molecule on their surfaces. This is because cancer cells change from epithelial to mesenchymal characteristics. To metastasize, cancer cells must undergo this epithelial-to-mesenchymal transition, gaining the ability to move more easily. During this change, they shed certain surface molecules, including EpCAM. Recent studies have reported lower-than-expected success for these developed methods in detecting circulating tumor cells.

In the system called EPISPOT, separation is based on proteins produced by the cell. Circulating tumor cells produce proteins specific to themselves. Detecting these proteins identifies the presence of tumor cells in blood.

There are also methods aiming to capture these cells using microchips. These methods capture a high proportion of the cells using very little blood. Testing is still ongoing.

Sources

1) D. Mavroudis, Circulating Cancer Cells,
Annals of Oncology 21 (Supplement 7): vii95–vii100, 2010.

2) Pantel, Klaus, and Catherine Alix-Panabières. “Detection Methods of Circulating Tumor Cells.” Journal of Thoracic Disease 4.5 (2012): 446–447. PMC. Web. 4 Oct. 2015.

3) Mikolajczyk, SD; Millar, LS; Tsinberg, P; Coutts, SM; Zomorrodi, M; Pham, T; Bischoff, FZ; Pircher, TJ (2011). "Detection of EpCAM-Negative and Cytokeratin- Negative Circulating Tumor Cells in Peripheral Blood.". Journal of oncology 2011: 252361

4) Kallergi, Galatea et al. “Epithelial to Mesenchymal Transition Markers Expressed in Circulating Tumour Cells of Early and Metastatic Breast Cancer Patients.” Breast Cancer Research : BCR 13.3 (2011): R59. PMC. Web. 4 Oct. 2015.

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

New Methods Based on Detecting Circulating Tumor Cells Aim to Diagnose and Treat Cancer at Much Earlier Stages

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy